id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-E-2582-0007,FDA,FDA-2015-E-2582,Determination of Regulatory Review Period for Purposes of Patent Extension; STRIVERDI RESPIMAT,Notice,Determinations,2017-12-26T05:00:00Z,2017,12,2017-12-26T05:00:00Z,2018-02-27T04:59:59Z,2017-12-26T16:25:50Z,2017-27710,0,0,0900006482d727f7
FDA-2015-E-2582-0006,FDA,FDA-2015-E-2582,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-06-05T04:00:00Z,2017,6,2017-06-05T04:00:00Z,,2017-06-05T19:36:52Z,,0,0,09000064826929b0
FDA-2015-E-2582-0005,FDA,FDA-2015-E-2582,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2017-04-07T04:00:00Z,2017,4,2017-04-07T04:00:00Z,,2017-04-07T14:16:49Z,,0,0,0900006482542f45